average monthly weight loss on glp 1 GLP-1 medications are changing the landscape of obesity treatment, but having realistic expectations is really important. Clinical trials showed weight loss of approximately: • ~15% body weight with semaglutide • ~ GLP-1 costs rise, but there

Youll receive an email with tracking information once your medication ships

These decisions are made by a healthcare provider based on individual patient considerations

April 18, 2026 Drugs Consultative Committee 68th meeting flags surrogate advertising of GLP-1 obesity drugs state regulators directed to enforce Medical Dialogues March 24, 2026 CDSCO tightens checks on generic semaglutide bans promotional activity, intensifies pharmacy surveillance Business Standard March 21, 2026 Patent expiry Day 1 8+ manufacturers launch simultaneously, prices fall up to 90% from branded versions CNBC March 17, 2026 ZydusLupin and ZydusTorrent licensing agreements announced ahead of patent expiry Pearce IP February 2026 Natco Pharma receives CDSCO approval for generic semaglutide Eris Lifesciences to commercialise Fierce Pharma December 2025 Sun Pharma receives first DCGI approval for generic semaglutide in India Noveltreat and Sematrinity Sun Pharma PR REGULATORY FRAMEWORK CDSCO Standards & Approval Requirements in India India's Central Drugs Standard Control Organisation (CDSCO) is the national drug regulator equivalent to the US FDA

GLP-1 receptor agonists are a class of medications originally developed and licensed for the treatment of type 2 diabetes mellitus, with some formulations also approved by the MHRA for weight management in adults with obesity or overweight with weight-related comorbidities, under specialist services as per NICE guidance (TA875)